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DObjectives: To compare the probability, and modes, of explantation for Carpentier-Edwards pericardial versus
porcine valves.
Methods: Our porcine series began in 1974 and our pericardial series in 1991, with annual prospective follow-
up. We used the Kaplan-Meier method and Cox regression for estimation and analysis of patient mortality, and
the cumulative incidence function and competing risks regression for estimation and analysis of valve durability.
Results: Through the end of 2010, we had implanted 506 porcine and 2449 pericardial aortic valves and 181 por-
cine and 163 pericardial mitral valves. The corresponding total andmaximum follow-up years were 3471 and 24,
11,517 and 18, 864 and 22, and 645 and 9. The corresponding probabilities (cumulative incidence function) of
any valve explant were 7%, 8%, 22%, and 8%, and of explant for structural valve deterioration were 4%, 5%,
16%, and 5% at 15 years for the first 3 series and at 8 years for the fourth (pericardial mitral valve) series. Using
competing risks regression for structural valve deterioration explant, with age, gender, valve size, and concom-
itant coronary bypass surgery as covariates, a slight (subhazard ratio, 0.79), but nonsignificant, protective effect
was found for the pericardial valve in the aortic position and a greater (subhazard ratio, 0.31) and almost signif-
icant (P ¼ .08) protective effect of the pericardial valve in the mitral position. Leaflet tear was responsible for
61% of the structural valve deterioration explants in the porcine series and 46% in the pericardial series.
Conclusions: Using competing risks regression, the pericardial valve had a subhazard ratio for structural valve
deterioration explant of less than 1 in both positions, approaching statistical significance in the mitral position.
The mode of structural valve deterioration was predominantly leaflet tear for porcine valves and fibrosis/
calcification for pericardial valves. (J Thorac Cardiovasc Surg 2012;144:1381-6)We began using Carpentier-Edwards (CE) porcine valves in
1974 and then migrated to the CE pericardial valves when
they became available (aortic in 1991 and mitral in 2000).
Surgeon preference for the pericardial valves was deter-
mined from tests performed by Edwards Laboratories and
Professor Carpentier, revealing greater in vitro durability
of pericardium. In 2003, we compared our experience
with CE aortic valve replacement (AVR) in 518 porcine
valves implanted from 1974 to 1996 and 1021 pericardial
valves implanted from 1991 to 2002, with a maximum
follow-up of 18 and 10 years, respectively.1
We found that the 10-year Kaplan-Meier freedom from
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The Journal of Thoracic and Carvalves (90% vs 97%, P ¼ .04), and concluded that, ‘‘The
current CE pericardial valve offers better midterm durabil-
ity than the traditional CE porcine valve. Its freedom from
SVD [structural valve deterioration] and reoperation makes
it our current bioprosthesis of choice for AVR in appropri-
ately selected patients.’’1
Dr Stuart Jamieson commented on our study, ‘‘Perhaps
the most valuable conclusion from this study, and others
similar to it, is that the durability of a tissue valve, in partic-
ular the durability of pericardial valves in the aortic position,
is better than 90% at 10 years. However, the 10-year test is
relatively easy to pass. Relative freedom from structural de-
terioration at 20 years will be the important milestone.’’2
We now have 8 years’ additional follow-up. Although we
have not yet achieved a 20-year estimate, we now have
a fairly precise durability comparison for AVR at 15 years.
In addition, we now also report on mitral valve replacement
(MVR). Although we have far fewer MVRs, the mitral po-
sition is known to have a greater risk of structural valve de-
terioration (SVD) and, thus, similar to an accelerated
fatigue tester, might provide a magnified comparison of
any differences in durability.MATERIALS AND METHODS
Clinical Material
Through the end of 2010, we had performed 506 CE porcine and 2449
CE pericardial isolated AVRs and 181 CE porcine and 163 CE pericardialdiovascular Surgery c Volume 144, Number 6 1381
FIGURE 1. Scatter plot of patient age during implant year, with local re-
gression (LOESS; locally weighted scatterplot smoothing) nonparametric
regression curves fit to the individual points. AVR, Aortic valve replace-
ment; MVR, mitral valve replacement.
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CE ¼ Carpentier-Edwards
CIF ¼ cumulative incidence function
CRR ¼ competing risks regression
KM ¼ Kaplan-Meier
MVR ¼ mitral valve replacement
SHR ¼ subhazard ratio
SVD ¼ structural valve deterioration
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Disolated MVRs. By ‘‘isolated,’’ we mean no concomitant or previous valve
replacement or repair procedures performed in another position. Concom-
itant coronary artery bypass grafting (CABG) was not an exclusion crite-
rion. The implant techniques were standardized for the entire series, with
the same aortic incision, myocardial protection, and the same surgical
group. There was an informative pattern to the distribution of patient age
over time (Figure 1). A gradual increase occurred in the mean age with
the porcine valve, as late SVD became known to be related to a younger
age. Then, a gradual revisiting of younger patient ages occurred as addi-
tional experience with the pericardial valve was gained—and with it, the
perception of improved durability.
Because our primary interest was in the long-term durability, we re-
stricted the subsequent analysis to operative survivors only, with 469 CE
porcine and 2356 CE pericardial isolated AVRs and 158 CE porcine and
154 CE pericardial isolated MVRs (Table 1). Since 1960, we have prospec-
tively interviewed all heart valve replacement patients at least annually for
their entire life. At the end of 2010, the maximum follow-up for these 4 pa-
tient series ranged from 9 to 24 years (Table 1). We considered valve pa-
tients lost to follow-up if they were not known to be dead or to have had
the valve explanted and had not responded to interview attempts for 2 years.
Because the present project involved only the study of existing records
and used only de-identified data, it qualified for exemption from institu-
tional reviewboard approval, according toExemption 45CFR46.101(b)(4).
Statistical Analysis
For the analysis of mortality, we use the Kaplan-Meier (KM) method3
and Cox regression analysis.4 For the analysis of valve explantation, we
used the cumulative incidence function (CIF), the appropriate method to
describe events with competing risks (death was considered a competing
risk, because it precludes the possibility of a future explant). The CIF esti-
mates the probability of a valve actually requiring explantation—before the
patient dies. Analogous to the use of Cox regression for multivariate anal-
ysis of risk factors for death, competing risks regression (CRR) was used
for the analysis of explantation. Instead of computing hazard ratios, such
as would occur with Cox regression analysis, CRR computes subhazard
ratios (SHRs), because the CIF is a subdistribution and not a complete dis-
tribution. This is because the probability of valve explant will not achieve
100%, as will the probability of patient death. The statistical packages used
in this analysis included R (R Foundation for Statistical Computing,
Vienna, Austria) and Stata (StataCorp, College Station, Tex): all figures
were produced using R, including the local regression (LOESS) nonpara-
metric regression curves. See the Appendix for a discussion of the compet-
ing risks and software options for computing CIF and CRR.
RESULTS
Patient Mortality
Unadjusted late mortality was lower for pericardial than
for porcine valves, in both AVR and MVR, although the1382 The Journal of Thoracic and Cardiovascular Surnumeric differences were not great: 81% versus 88% at
15 years for AVR (P¼ .02) and 50% versus 57% at 8 years
forMVR (P¼ .04). Separate Cox regression analyses of late
survival for AVRandMVR—using valve type, patient age at
implantation, gender, CABG, and valve size (Table 2)—
showed the pericardial valve to be protective (hazard
ratio<1) for mortality, significantly for MVR (P ¼ .003)
but not quite for AVR (P ¼ .054).Valve Explantation
Our main interests in the present study were the end-
points of overall explantation and explantation for SVD.
All explants. For each position, the porcine valve had
a greater probability (CIF) of overall explantation than the
pericardial valve at 10 years (Figure 2). However, the prob-
abilities of valve explantation by 15 years were similar in
the aortic position. The CIF probability of explantation by
15 years after porcine and pericardial AVR was 7% 
1.3% (standard error [SE]) and 8%  1.2% (Figure 2), re-
spectively (P ¼ .12, using univariate CRR). The probabili-
ties of explantation were 22%  3.7% by 15 years for
porcine MVR and 8%  3.8% by 8 years for pericardial
MVR (P ¼ .03, using univariate CRR).
Explants for SVD. The CIF probability of explantation for
SVD by 15 years after porcine and pericardial AVRwas 4%
 1.0% (SE) and 5%  0.9% (Figure 3), respectivelygery c December 2012
TABLE 1. Clinical material for operative survivors
Aortic replacement Mitral replacement
Pericardial Porcine P value Pericardial Porcine P value
Implant years 1991-2010 1976-1994 2000-2010 1974-2003
Valves (n) 2356 469 154 158
Mean age 72.9 73.8 .08 70.4 68.0 .09
Male (%) 62.5 61.6 .73 57.1 39.2 <.01
Mean valve size (mm) 24.1 23.4 <.01 29.2 30.4 <.01
CABG (%) 48.2 38.8 <.01 37.7 31.0 .22
Follow-up
Patient-years 11,514 3470 645 863
Mean (y) 4.9 7.4 4.2 5.5
Maximum (y) 18 24 9 22
Completeness (%) 94 87 93 87
CABG, Coronary artery bypass grafting.
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D(P ¼ .35, using univariate CRR). The probabilities of ex-
plant for SVD were 16%  3.3% (SE) by 15 years for por-
cine MVR and 5% 3.2% by 8 years for pericardial MVR
(P¼ .13, using univariate CRR). Using CRR for risk adjust-
ment, with age, gender, valve size, and CABG as covariates,
the pericardial valve was protective (SHR<1) for SVD ex-
plant in both positions (Table 3). The difference was almost
statistically significant (P ¼ .08) in the mitral position
(SHR ¼ 0.31) but was not in the aortic position (SHR ¼
0.79). Age was a highly significant protective factor for
SVD explant in both positions (P<.001); for AVR, CABG
was almost significantly protective (P ¼ .07). The mode of
failure was different between the 2 valve types: the numbers
of leaflet tears and fibrosis/calcificationwere 23 and 15 (61%
were leaflet tears) for the porcine series (AVR and MVR
combined) and 11 and 13 (46% were leaflet tears) for the
combined pericardial series.
DISCUSSION
In our previous report,1 only 6 aortic pericardial valves
had been in place longer than 10 years. We now have 213
such patients, and the AVR durability advantage we previ-
ously observed at 10 years seemed to be attenuated at 15
years (Figure 2). Dr Jamieson’s comment2 was that 90%
durability at 10 years is fairly easy to pass, but the challengeTABLE 2. Multivariate Cox regression of late mortality with CE
tissue valves
Risk factor
AVR MVR
HR (95% CI) P value HR (95% CI) P value
Pericardial valve 0.88 (0.774-1.00) .054 0.53 (0.34-0.81) .003
Patient age 1.05 (1.04-1.06) <.001 1.05 (1.03-1.08) <.001
Male gender 1.22 (1.05-1.42) .011 1.14 (0.79-1.64) .486
CABG 1.13 (1.00-1.27) .045 1.42 (0.99-2.01) .052
Valve size 0.96 (0.92-1.00) .028 0.97 (0.88-1.06) .468
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting; CE,
Carpentier-Edwards; CI, confidence interval; HR, hazard ratio; MVR, mitral valve
replacement.
The Journal of Thoracic and Carwould be for 20 years. The CIF for explantation was still
lower than 10% at 15 years in the aortic position, for both
valve types (Figure 2). Thus, we continue to monitor these
patients, and await our 20-year results.
A recent innovative study, fueled by a meta-analysis (8 re-
ports, 2685 patients, 12,250 patient-years) of AVR with CE
pericardial valves,5 used computer simulations to calculate
‘‘.the ‘actual’ or lifetime risks of valve-related events and
reoperation after valve implantation.’’ Thismethod simulates
the various states of mortality and morbidity that a valve
might be in at any time after implantation and conforms ex-
actly to the concept of CIF, rather than the KMmethod, to es-
timate SVD.The investigators found that ‘‘the lifetime risk of
a reoperation due to SVD reduced with advancing age of im-
plantation and was 17% and 5%, respectively, for 65- and
75-year-old males.’’ This agrees well with our finding of
5% SVD explantation at 15 years for our aortic CE pericar-
dial patients, who had an average age of 73 years.
Other aortic porcine valves have been found to have ex-
cellent long-term durability, including the third-generationFIGURE 2. Cumulative incidence function estimates of explant for any
reason in operative survivors.
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FIGURE 3. Cumulative incidence function estimates of explant for struc-
tural valve deterioration (SVD) in operative survivors.
TABLE 3. Multivariate competing risks regression of explantation for
SVD with CE tissue valves
Risk factor
AVR MVR
SHR (95% CI) P value SHR (95% CI) P value
Pericardial valve 0.79 (0.43-1.45) .448 0.31 (0.08-1.13) .075
Patient age 0.94 (0.92-0.95) <.001 0.93 (0.90-0.95) <.001
Male gender 1.39 (0.62-3.14) .422 0.40 (0.14-1.16) .092
CABG 0.50 (0.24-1.05) .069 1.29 (0.50-3.34) .656
Valve size 0.96 (0.82-1.12) .608 1.04 (0.84-1.29) .762
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting; CE,
Carpentier-Edwards; CI, confidence interval; MVR, mitral valve replacement; SHR,
subhazard ratio; SVD, structural valve deterioration.
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The KM percentage of reoperation for SVD by 15 years
was 12%  1.8% (SE). This was somewhat greater than
our values of 4% and 5%; however, these patients were
younger (67 vs 73 years), and the KM method produces
greater failure rates than the CIF method (see the
Appendix).
A very recent observational study of pericardial versus
porcine AVR that concentrated on survival concluded that
‘‘Despite the better hemodynamic performance docu-
mented in prior investigations, pericardial valves do not
confer any survival advantage over porcine valves in pa-
tients aged 65 years or older undergoing aortic valve re-
placement.’’7 These investigators observed a slight
survival advantage for porcine compared with pericardial
valves. We found a slight risk-adjusted advantage, although
not quite significant (P¼ .054), in the survival of pericardial
versus porcine valves in the aortic position (Table 2). How-
ever, the numeric difference was relatively small (7% at 15
years). One reason for the discrepancy could have been be-
cause our AVR porcine cases were performed in an earlier,
almost nonoverlapping, implant era, compared with theirs
(1974-1994 vs 1993-2007).Study Limitations
It is always challenging to draw data-supported conclu-
sions from observational series. The major issue with non-
randomized comparisons is the possibility of selection
bias. Although the valve types we studied were not random-
ized, theywere also not concurrent. Rather, the 2 valve types
were used consecutively (Figure 1); thus, the selection bias
should have been minimal, because each valve type was
used in virtually all tissue valve recipients during its era of
use. However, this does implicate as possible confounders
other variables that changed systematically between the1384 The Journal of Thoracic and Cardiovascular Sur2 implant eras. We used only 4 factors for risk adjustment
(Tables 2 and 3), and many other patient risk factors could
be considered in the risk adjustment of a comparison of
observational data such as ours. However, age is the most
significant factor known to affect tissue valve durability
and was accounted for in the analysis.
Although the CIF method is appropriate for estimating
the probability of nonfatal events, a comparison between
the CIFs of different valves can be problematic if the death
rates are dissimilar, because a greater death rate will tend to
reduce the CIF of valve explantation. However, in these se-
ries, the mortality was greater with the porcine than with the
pericardial valves (Table 2). Thus, the lower mortality for
the pericardial valve tended to increase the CIF of SVD
explants, relative to the porcine valve. If this were not the
case, it would only have increased the observed SVD
explant advantage of the pericardial valve.
A criticism of the present study could be that the CE por-
cine valves we studied were first generation, and the pericar-
dial valves have been evolving recently. However, most of
the pericardial valves in the present study were also first
generation, with the newer Magna version in predominant
use only in the last 2 years of our study. Specifically, in
the present study, 91% of the pericardial aortic valves
were the original model 2700, 95% of the pericardial mitral
valves were model 6900, 99.8% of the porcine aortic valves
were the original model 2625, and 93% of the porcine mi-
tral valves were the original model 6625. It will take some
time to determine the relative performance of the latest gen-
erations of porcine and pericardial valves.
CONCLUSIONS
Using CRR, the CE pericardial valve had a SHR for SVD
explant of less than 1 in both positions compared with the
CE porcine valve. The difference was nearly statistically
significant for MVR. The mode of SVD was predominantly
leaflet tear for the porcine valve and fibrosis/calcification
for the pericardial valve.
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DURABILITY (CIF) VERSUS PATIENT SURVIVAL
(KM)
In this Appendix, we provide the justification for the use
of the cumulative incidence function (CIF) as an estimator
of the probability of valve explantation. This method is less
well known than the widely used Kaplan-Meier (KM) esti-
mate,3 which produces a survival (or mortality) curve in the
presence of censoring (ie, before all the individuals in a se-
ries have died). The true mortality curve—after all patients
have died—would be the cumulative deaths plotted versus
time. This curvewould increase at each death, by an amount
equal to the percentage of the whole population that had
died at that time, increasing from 0% to 100% at the last
death (ie, the curve that the KM attempts to approximate
for an ongoing series, before all patients have died).
For a nonfatal event, such as valve explantation, the cor-
responding estimate is the CIF, which estimates the per-
centage explanted over time in the presence of censoring
(ie, before all the valves have ceased functioning). The
true explant curve—after all the valves have ceased
functioning (because of valve explantation or patient
death)—would be the cumulative explants plotted versus
time. This curve would increase with each explant by an
amount equal to the percentage of the whole population
explanted at that point, increasing from 0% to a percentage
less than 100%, at the point of the last explant (ie, the
curve that the CIF attempts to approximate for an ongoing
series).The Journal of Thoracic and CarThe KMmethod is often used to estimate the incidence of
explantation; however, this overestimates the true explant
incidence.8-12 To illustrate this, we used both AVR series
combined (Figure 4). Each valve can be in 1 of 3 states at
any point after surgery. From bottom to top in Figure 4,
these states are (1) valve function terminated by explanta-
tion; (2) valve function terminated by patient death; and
(3) valve still functioning. The lowest curve in Figure 4 is
the CIF estimate of explantation. For comparison, the KM
estimate of explantation is superimposed as a dashed line,
and can be seen to overestimate the percentage of explants
that will actually occur.
What does the KM curve estimate? First, it only works if
death and explantation are independent,13 which in these
situations is a false assumption, because younger patients
will have lower death rates and greater structural valve de-
terioration rates than older patients. If explantation and
death were independent, the KM method would estimate
the theoretical durability of the valve in the event that no
patient died.13 A thought experiment might clarify this
idea. Imagine we used a biologic valve in 2 series of iden-
tical patients. The first group is given a magic elixir that pre-
vents death—until after the tissue valve has failed and been
explanted. The KM curve would provide the estimate of the
explant curve in that series. The elixir is withheld from the
second group, and death takes its usual course. The CIF
curve would provide the estimate of the resulting failure/
explant curve, which would be lower than the previous
KM curve. Thus, the KM curve does not provide a true
probability of explantation, because most patients will die
before their valve fails. The CIF takes into account thediovascular Surgery c Volume 144, Number 6 1385
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estimate of the probability of the occurrence of
explantation.
A patient cares less about the theoretical durability of the
valve than about the ‘‘practical’’ durability of the valve (ie,
will it last long enough to keep me alive until I die of some
other cause?). However, we must focus not only on such
overall values, but also on estimates that are individualized
to a patient, taking into consideration other variables, espe-
cially age. Thus, from a patient standpoint, it is clear that the
risk of structural valve deterioration should be balanced
against the risk of survival. Similar to Cox regression anal-
ysis for mortality, the method of competing risks regression1386 The Journal of Thoracic and Cardiovascular Sur(CRR) provides the appropriate patient-specific estimates
for explantation and structural valve deterioration.
Software has been developed for the implementation of
the CIF and CRR. For R (R Foundation for Statistical Com-
puting, Vienna, Austria), from the cmprsk package, the
function cuminc implements CIF and the function crr im-
plements the CRR model of Fine and Gray.14 In the timereg
package, the function comp.risk for CRR is based on
Scheike and Zhang,12 and it contains the Fine and Gray
model as a special case. For Stata (StataCorp, College Sta-
tion, Tex), the command stcompet produces the CIF; for
CRR, stcrreg implements the Fine and Gray method,14
and stcompadj is based on the Cox model.4gery c December 2012
